title: Why statin therapy may increase the risk for posttransplantation squamous cell carcinoma.
abstract: We suggest that surveillance for squamous cell cancer might be particularly useful for transplant patients receiving statin therapy. We recommend that development of non melanoma skin cancer should be specified as a secondary endpoint in future large endpoint statin trials, and suggest that in transplant patients the adverse effects of statin drugs may outweigh benefits, especially in women and the elderly, a subset of population in which even individuals at high risk for cardiovascular disease have shown no trend to net benefit from statins.
authors.affiliation: Comando Brigata Alpina Julia, Medical Service, 8 Via S. Agostino, Udine, 33100, Italy. lumasci@libero.it
authors.forename: Luca
authors.initials: L
authors.lastname: Mascitelli
authors.forename: Francesca
authors.initials: F
authors.lastname: Pezzetta
authors.forename: Mark R
authors.initials: MR
authors.lastname: Goldstein
mesh_terms: D000368:Aged; D002294:Carcinoma, Squamous Cell / Q000453:epidemiology*; D002986:Clinical Trials as Topic; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy / Q000453:epidemiology* / Q000276:immunology; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D007165:Immunosuppression Therapy; D016377:Organ Transplantation; D018570:Risk Assessment; D012307:Risk Factors; D012878:Skin Neoplasms / Q000453:epidemiology*
chemical_list: D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors